Logo Image

Brendan Boyle, MD

Articles by Brendan Boyle, MD

AJMC original research clinical

The Biosimilar Shift: Trending Infliximab Biosimilar Utilization and Associated Cost Savings for Commercial Insurance

BySamantha R. Paglinco, DO,Mahmoud Abdel-Rasoul, MS, MPH,Megan McNicol, PharmD, BCACP,Morgane C. Mouslim, DVM, ScM,Brendan Boyle, MD,Jennifer L. Dotson, MD, MPH,Hilary K. Michel, MD,Ross M. Maltz, MD

Infliximab biosimilars created price competition causing insurance claims costs for infliximab originator and infliximab biosimilars to decrease, generating significant savings to the health care system.

Latest Updated Articles